Please assess the completion status of the following clinical trial:

Trial Title: CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing primary liver transplantation.~* Patients older than 18 years.~* Patients with a hepatorenal syndrome type I or II~* eGFR \< 50 ml/min at the time point of transplantation~* Serum creatinine levels \> 1.5 mg/dL at the time-point of transplantation~Exclusion Criteria:~* Patients with pre-transplant renal replacement therapy \> 14 days.~* Patients with a known hypersensitivity to mTOR-inhibitors.~* Patients with a known hypersensitivity to mycophenolate acid.~* Patients with a known hypersensitivity to anti CD 25-monoclonal antibodies.~* Patients with platelets \< 50.000/nl.~* Patients with triglycerides \> 350 mg/dl and cholesterol \> 300 mg/dl refractory to optimal medical treatment prior to initiation of therapy with mTOR inhibition.~* Severe systemic infections and wound-healing disturbances prior to inclusion.~* Multiple organ graft recipients.~* Patients with signs of a hepatic artery stenosis directly prior to initiation of therapy with Sirolimus.~* Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.~* Patients under guardianship (e.g. individuals who are not able to freely give their informed consent).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Prior to reperfusion 500 mg Prednisolone will be administered i.v.. After the transplantation, a combination of anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure), and MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake) will be applied. Earliest, on day 10 after LT Sirolimus will be introduced aiming at 24 hours trough-levels for Sirolimus between 4 and 8 ng/mL. Steroids will be started on day 1 after transplantation with 1mg/kg BW and will be tapered every 2 days for 5 mg to a dosage of 20 mg and for 2.5 mg every two days to 7.5 mg. Thereafter the dosage will be reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter. Additionally, every patient with risk constellation will receive cytomegalovirus (CMV) prophylaxis and prophylaxis against Pneumocystis carinii infection during the first 3 months after liver transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).